New Delhi: Through a recent decision, the Department of Pharmaceuticals (DOP) has rejected the review application filed by Geltec Private Limited against National Pharmaceutical Pricing Authority (NPPA) for price fixation of its formulations “Ibuprofen 400mg Soft Gelatin Capsules and Ibuprofen 200mg Soft Gelatin Capsules”.

However, the NPPA did not fix the retail prices of the said formulations and directed the company to follow the ceiling price of Ibuprofen 400mg and 200mg hard gelatin capsules notified in 2018.

Having been aggrieved by the response of the NPPA, Geltec submitted the review application to the department for separate retail prices for its formulations. As per the para 31 of the DPCO, any person aggrieved by any notification issued or order made under paragraph 4, 5 and 6 of the DPCO, may apply to the Government for a review of the notification or order.

In the instant case, the petitioner, GELTEC filed a review against the NPPA which was simply a reply to the company against its Form I application. Noting this, DOP rejected the company's plea

"Filing of a review application against a letter is not as per the provisions laid down in the DPCO. Hence, the review application is liable to be rejected," reads the order.

Subsequently, DOP rejected the plea filed by Geltec against NPPA.

Also Read: Refix ceiling price of Zydus Healthcare Tiotropium Inhalation: DoP directs NPPA